Apr 15, 2025 8:00am EDT Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Mar 31, 2025 8:00am EDT Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 3, 2025 Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
December 20, 2023 Navigating the Future of Pain Management: Ensysce Biosciences’ Innovative Approach